Trial Profile

Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens (REMEMBER)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efavirenz (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Isoniazid (Primary) ; Isoniazid/rifampicin (Primary) ; Rifampicin/isoniazid/pyrazinamide/ethambutol (Primary) ; Pyridoxine
Indications HIV infections; HIV-1 infections
Focus Therapeutic Use
Acronyms REMEMBER

Most Recent Events

26 Feb 2021 Status changed from recruiting to completed, as per Results published in the Clinical Infectious Diseases
26 Feb 2021 Results published in the Clinical Infectious Diseases
30 Oct 2012 New source identified and integrated (Clinical Trials Registry - India; CTRI2012-11-003088).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com